Every IV therapy appointment is designed to be simple, clean, comfortable, and clinically guided
Another study (PRAISE-2) randomized patients with NYHA Class III (80%) or IV (20%) heart failure without clinical symptoms or objective evidence of underlying ischemic disease, on stable doses of ACE inhibitors (99%), digitalis (99%), and diuretics (99%), to placebo (n=827) or amlodipine besylate (n=827) and followed them for a mean of 33 months
Patients should consult a physician before proceeding if any of the following apply: Pregnancy or active breastfeeding Known allergy to glutathione or any infusion component Severe kidney or liver disease Asthma, as some formulations may trigger bronchospasm in sensitive individuals Current use of platinum-based chemotherapy drugs, which can interact with high-dose glutathione Improved energy and reduced fatigue post exercise, particularly with more advanced cellular support solutions such as NAD+ IV Therapy Edmonton
Improper injection techniques increase the risk of infection, making sterile practices essential